biology-products/coverslips-for-microarrays-from-ge-healthcare--formerly-amersham-biosciences-4286-1/;msg90356

Breaking Biology Technology:YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2 YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3 YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4 YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5 Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2 Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3 Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2 Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3 Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4 Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5 Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6 Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 2 Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 3 Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 4

[0] YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES [0] Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner [0] Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain [0] Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea

Breaking Medicine Technology:Indiana Blood Center Taps tw telecom for Data, Internet and IP Telephony Services 2 National Ergonomics Expo Sees Immediate 93% Exhibit Space Renewal for 2010; Equipois, Herman Miller, Neutral Posture, REDpoint International Win 2009 Attendees' Choice New Product Awards 2 NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock 2 Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 14351 1 Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 14351 2 Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 14351 3 Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 14351 4 Lincare Holdings Inc Extends Terms of Employment Agreements with Executive Officers 5219 1 Lincare Holdings Inc Extends Terms of Employment Agreements with Executive Officers 5219 2 Bausch 26amp 3B Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux 5214 1 Bausch 26amp 3B Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux 5214 2

[0] Indiana Blood Center Taps tw telecom for Data, Internet and IP Telephony Services [0] National Ergonomics Expo Sees Immediate 93% Exhibit Space Renewal for 2010; Equipois, Herman Miller, Neutral Posture, REDpoint International Win 2009 Attendees' Choice New Product Awards [0] NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock